Fresenius Medical Care Ag shares fall 1.02% premarket after leading EASYGEN consortium for CAR-T cell therapy.

Fresenius Medical Care Ag dropped 1.02% in premarket trading. The company is leading a new consortium, EASYGEN, aimed at accelerating the manufacturing of CAR-T cell therapy, making it more cost-effective, and improving patient access across Europe. The project is a public-private partnership, with €8 million in funding provided by the EU through the Innovative Health Initiative (IHI). Additionally, Charles River Laboratories International, Inc. has joined the EASYGEN Consortium, further supporting the effort to produce CAR-T cell therapies faster and more affordably.